5 results about "Entacapone" patented technology

The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising(i) levodopa in an amount ranging from 50 mg to 300 mg,(ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and(iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight. Pharmaceutical dosage form used in said method are also disclosed.

The present invention provides the use of entacapone, an entacapone derivative, or a stereoisomer, hydrate, or pharmaceutically acceptable salt thereof, in a human in need thereof for treating an injury or promoting wound healing or tissue regeneration.

The application belongs to the technical field of medicine, and specifically provides an entero-soluble ibrexin tablet with high bioavailability and a preparation method thereof. The entero-soluble tablet comprises a tablet core and an enteric coating, wherein the tablet core comprises an ibrexin coating compound, microcrystalline cellulose and magnesium stearate, and the ibrexin coating compound comprises ibrexin or a pharmaceutically acceptable salt thereof, an acid regulator, povidone and cross-linked sodium carboxymethyl cellulose. The ibrexin entero-soluble tablet of the application can make the drug reach the end of the small intestine or the colon for release, thereby avoiding the metabolism of cytochrome P450 (CYP) 3A, and at the same time, the acid regulator can locally provide an acidic environment for the active ingredient, so that the ibrexin is rapidly dissolved and released, and the side effects such as vomiting in the gastrointestinal tract are reduced.

The application discloses a detection method and application of entacapone double-dopa tablets, and operation steps of the detection method include sample pretreatment, chromatographic separation detection and quantification; the sample pretreatment comprises the following operation steps: grinding the entacapone double-dopa tablets into uniform fine powder, precisely taking a proper amount of tablet powder, adding a diluent to dissolve and stabilize, performing ultrasonic treatment, then constant volume and filtration, and taking the filtrate as a test sample solution; a solvent in the diluent is a mixed solution of methanol and water, and solutes in the diluent include sodium metabisulfite and disodium ethylenediaminetetraacetate. The application can realize synchronous analysis of entacapone, levodopa and carbidopa with rapidness, high separation degree, high sensitivity and high stability, so as to meet strict quality control requirements of the compound preparation.

The present invention pertains to: a maturation promoter for stem cell-derived non-mature nerve cells, the maturation promoter being characterized by containing at least one compound selected from the group consisting of asenapine and a salt, solvate, or derivative thereof, and entacapone and a salt, solvate, or derivative thereof; and a method for promoting maturation of stem cell-derived non-mature nerve cells, the method being characterized by making stem cell-derived non-mature nerve cells coexist with the maturation promoter.